Genentech’s vamikibart sustains vision gains at 52 weeks, but mixed Phase III results complicate FDA review
Genentech's vamikibart sustained vision gains at 52 weeks, but mixed Phase III results leave questions ahead of a July 2027 FDA decision.
Medical Devices & Diagnostics